Annexon has been granted a patent for anti-C1q antibody Fab fragments to inhibit synapse loss. The method involves administering the fragments to patients experiencing adverse synapse loss. The fragments contain specific heavy and light chain sequences. GlobalData’s report on Annexon gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Annexon, NSAID cancer drugs was a key innovation area identified from patents. Annexon's grant share as of May 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.
Method of inhibiting synapse loss using anti-c1q antibody
A recently granted patent (Publication Number: US11999779B2) discloses a method for inhibiting synapse loss by administering an antibody Fab fragment that binds to C1q, targeting patients experiencing adverse synapse loss due to neurodegenerative disorders like Alzheimer's disease. The antibody Fab fragment, composed of specific heavy and light chain sequences, aims to inhibit complement activation and prevent further synapse loss in affected individuals. Additionally, the method includes the administration of neural progenitors or neurogenesis enhancers to support synaptic health and function.
Furthermore, the patent also covers a method for treating diseases associated with C1q-mediated activation of the classical complement pathway by administering the same antibody Fab fragment to individuals in need of such treatment. The diseases targeted include various neurodegenerative disorders linked to synapse loss, as well as inflammatory diseases, autoimmune diseases, complement-associated eye diseases, and metabolic disorders. The antibody Fab fragment, with a specific dissociation constant for mouse C1q, can effectively bind to C1q and modulate the classical complement pathway, offering a potential therapeutic approach for a wide range of conditions. Additionally, the humanized version of the antibody Fab fragment is also encompassed within the patent claims, highlighting its potential for clinical applications in diverse disease settings.
To know more about GlobalData’s detailed insights on Annexon, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
